Tarsus Pharmaceuticals, Inc. TARS Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)

Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) at other companies

Bausch + LombBLCO

$215M+0.5%

HRO

HarrowHROW

$16.58M+3.0%

PTH

Pelthos TherapeuticsPTHS

$3.82M—

FAQ

What is Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets - expected amortization expense (year one)?

Tarsus Pharmaceuticals, Inc. (TARS) reported finite-lived intangible assets - expected amortization expense (year one) of $961K in Q2 2026.

How has Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets - expected amortization expense (year one) changed year-over-year?

Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets - expected amortization expense (year one) decreased by 0.0% year-over-year, from $961K to $961K.

What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets - expected amortization expense (year one)?

Over 2 years (2023 to 2025), Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets - expected amortization expense (year one) has grown at a 55.0% compound annual growth rate (CAGR), from $400K to $961K.

What does finite-lived intangible assets - expected amortization expense (year one) mean?

This metric forecasts the amortization expense expected to be recognized in the upcoming fiscal year for intangible assets with finite useful lives. It provides visibility into the non-cash earnings impact of previously acquired intangible assets. Analysts use this to refine future earnings projections and cash flow models.